Leonurus cardiaca L. — A comprehensive evidence-based clinical monograph covering cardiotonic, antihypertensive, anti-arrhythmic, sedative, neuroprotective, nephroprotective and uterotonic pharmacology of leonurine and stachydrine in aerial part preparations.
Leonurus cardiaca L. is a perennial herb of the Lamiaceae family native to most of Europe and central Asia. Its two vernacular names reveal its dual therapeutic scope: cardiaca (cardiac plant) reflects its centuries of use for heart and circulatory disorders, while motherwort reflects its role in gynaecology and neonatology across the Leonurus genus. [1] The principal active molecules are the alkaloids leonurine and stachydrine, alongside iridoids, labdane diterpenes, flavonoids, phenylethanoide glycosides and triterpenic acids.
Motherwort carries two of the most revealing vernacular names in European phytomedicine. The Latin epithet cardiaca encodes millennia of use as a heart tonic, while the English motherwort — literally "mother plant" — marks its long-standing role in women's medicine across Europe and Asia. Modern pharmacological research has validated both traditions with molecular precision, identifying the alkaloid leonurine as the principal cardioprotective and uterotonic agent, and GABA-A–interacting compounds as the basis for its anxiolytic properties. [1]
The name Leonurus derives from Greek for "lion's tail," describing the plant's tall, mane-like flowering spikes. Cardiaca is the direct Latin for cardiac — heart — making this one of the only pharmacopoeial plants whose Latin name is itself a pharmacological descriptor. The English name motherwort directly encodes its obstetric use. [1]
European herbalists from the medieval period onward prescribed motherwort for palpitations, anxiety-driven heart disorders, and menstrual irregularities. Its inclusion in the French Pharmacopoeia (List A, flowering tops) confirms this long-established medical tradition at the regulatory level.
In TCM, Yi Mu Cao (Herba Leonuri) is a major gynaecological remedy for menstrual disorders, postpartum haemorrhage, and oedema. Leonurus japonicus HOUTT. is the primary species used in China, with injection preparations studied in multi-centre trials for post-caesarean haemorrhage prevention. [16],[17]
The EMA Committee on Herbal Medicinal Products published a formal assessment report on Leonurus cardiaca herba in 2010, confirming traditional use status and noting the equivalence of four related Leonurus species for phytotherapeutic purposes. [26]
Historical Timeline
A guanidine alkaloid unique to the Leonurus genus, leonurine (SCM-198) is the principal pharmacodynamic molecule driving cardiovascular, neurological and renal protection.
Molecular Identity
"Leonurine is the pharmacological fingerprint of the Leonurus genus — detectable in all three major species: cardiaca, japonicus and leonurus."
From the primary literature — Kuchta et al. 2012 [29]
Leonurine is a guanidine alkaloid — a nitrogen-containing compound structurally related to stachydrine but with distinct multi-system pharmacology. It is quantified by HPLC and 1H-qNMR in standardisation assays. [28],[29]
Metabolite profiling in rats (Zhu et al. 2014) has characterised leonurine's systemic metabolites using LC/MS and NMR, providing a complete metabolic map for preclinical safety and efficacy interpretation. [13]
Important Note — Uterotonic Caution
Leonurine also mediates the plant's uterotonic and oxytocic effects. This is the pharmacological basis for the absolute contraindication in pregnancy. All uterotonic activity is attributed to leonurine and related alkaloids, particularly in Leonurus japonicus. [15],[16]
The aerial parts — flowering tops — are the sole part used, available in two principal pharmaceutical preparations.
Dried flowering tops (summitas florida) — the part listed in the French Pharmacopoeia (List A). Minimum 0.2% flavonoids expressed as hyperoside. Available as mother tincture and alcoholic tincture. Standardised extracts exist for clinical research but are less commonly commercially available than tincture forms.
An oil extract of aerial parts was used in the primary clinical trial on hypertension (Shikov et al., 2011). [12] This preparation format — an oleolite or fixed-oil macerate — differs pharmacokinetically from alcohol tinctures and EPS. Its standardisation method is not commercially harmonised. For clinical equivalence claims, verify preparation type.
Dosage data from the WHO monograph, French Pharmacopoeia, and the primary clinical literature. Always apply under qualified healthcare supervision.
| Preparation | Dose | Frequency | Notes |
|---|---|---|---|
| Mother tincture (TM) | Standard tincture dose per product | 2–3× daily | Most common commercial form. Aerial parts, minimum 0.2% flavonoids as hyperoside. [2] |
| Alcoholic tincture | Per product specification | 2–3× daily | As per French Pharmacopoeia List A (flowering tops). Quality marker: hyperoside content. [5] |
| Oil extract (clinical) | As per Shikov et al. 2011 | Per trial protocol | Administered in hypertension with anxiety and sleep disorders. Significant reduction in BP, anxiety, and sleep disturbance documented. [12] |
| Dry standardised extract | Not harmonised commercially | Per product | Research-grade extracts standardised to leonurine or stachydrine content by HPLC. [3],[4] |
⚠ Contraindicated in pregnancy. Not for use without medical supervision in patients on antihypertensive or anticoagulant therapy.
Aerial parts contain a complex multi-class phytochemical profile. Key marker compounds are stachydrine and leonurine, quantifiable by HPLC and 1H-qNMR. [2],[3],[4],[5],[6]
Total phenolic and flavonoid contents of L. cardiaca correlate directly with antioxidant capacity in DPPH radical scavenging assays. [22]
Mildly cardiotonic via bufanolide glucosides. Hypotensive action attributable to lavandulifolioside. Exerts a negative chronotropic effect (slows heart rate), prolongs the P-Q interval, Q-T intervals and QRS complex. [7]
Documented anti-arrhythmic activity mediated by stachydrine and triterpenic acids (oleanolic acid and ursolic acid). Cardiac electrophysiology studies confirm inhibition of arrhythmia-inducing electrical patterns in primary and refined extracts. [8]
Leonurine reduces acute myocardial ischaemia via a liver-cardiac crosstalk mechanism. Protects against myocardial apoptosis induced by hypoxia. Mitochondrial oxidative phosphorylation in heart tissue is supported by flavonoid fraction. [9],[10],[11]
Clinical evidence from Shikov et al. (2011): motherwort oil extract significantly reduced blood pressure in hypertensive patients, with particular efficacy when hypertension was accompanied by anxiety and sleep disorders — a phenotype well matched to the plant's multitarget profile. [12]
Multi-compound GABA-A receptor modulation via isoleosibirine (labdane diterpene), 7R-chloro-6-deoxy-harpagide (iridoid), lavandulifolioside (phenylethanoide), stachydrine and leonurine. Clinically active in tachycardia of hyperthyroidism and neurovegetative functional disorders. [14]
Documented uterotonic and oxytocic activity, especially pronounced in Leonurus japonicus. Used in TCM in a multi-centre study to prevent postpartum haemorrhage after caesarean section. This activity underlies the absolute contraindication in pregnancy. [15],[16]
Leonurine ameliorates LPS-induced acute kidney injury by suppressing ROS-mediated NF-κB signalling. Also demonstrated to reduce kidney fibrosis by suppressing the TGF-β and NF-κB pathways in a unilateral ureteral obstruction mouse model. [18],[19]
Leonurine improves cognitive dysfunction by antagonising excitotoxic glutamate insults and inhibiting autophagy. Protects neuronal cells against ischaemia-induced injury via Cx36/CaMKII pathway modulation in PC12 cell models. [20],[21]
Total phenolic and flavonoid fractions contribute significant DPPH radical scavenging activity. [22] Immunomodulatory potential documented in relation to endothelial cells and platelet function. [23] Anti-inflammatory and analgesic properties confirmed in the primary review literature. [2]
Documented antibacterial activity. Inhibition of platelet aggregation and vasodilatory effects attributed to leonurine and stachydrine. Leonurine's antiplatelet and vasodilatory actions are clinically relevant in the context of cardiovascular combination therapy, requiring professional monitoring. [13]
Indications from the WHO monograph, French Pharmacopoeia, primary clinical literature and the EMA assessment report (2010).
Multi-target mechanisms operating across four biological systems simultaneously — one of the defining features of the Leonurus phytochemical complex.
Lavandulifolioside prolongs P-Q, Q-T intervals and QRS complex, acting as a cardiac conduction modulator. This electrophysiological profile underpins both the negative chronotropic and anti-arrhythmic effects. Bufanolide glucosides provide mild cardiac glycoside-like tonic activity. [7]
Standardised GABA-A receptor binding assays (Rauwald et al. 2015) confirmed direct binding by isoleosibirine, 7R-chloro-6-deoxy-harpagide, lavandulifolioside, stachydrine and leonurine — explaining sedative, anxiolytic and sleep-promoting effects without a single dominant compound. [14]
Leonurine suppresses NF-κB signalling in both renal and cardiac contexts, reducing oxidative stress, inflammation and fibrotic remodelling. In the kidney, it simultaneously targets TGF-β to prevent tubulointerstitial fibrosis — a mechanism also relevant in post-ischaemic cardiac remodelling. [18],[19]
In neuronal PC12 cells, leonurine exerts neuroprotective effects by targeting connexin-36 (Cx36) and CaMKII, reducing oxygen-glucose deprivation injury. This molecular specificity distinguishes leonurine from generic antioxidant neuroprotection. [21]
Leonurine protects against cognitive dysfunction by antagonising excitotoxic glutamate signalling and inhibiting pathological autophagy in hippocampal models — two separate mechanisms converging on neuroprotection. [20]
Leonurine inhibits platelet aggregation, acts as a vasodilator, and inhibits apoptosis induced by myocardial hypoxia. These combined vascular effects produce a synergistic anti-thrombotic and cardioprotective output that no single molecular target could achieve independently. [13]
Structural and phytochemical differences exist between the major Leonurus species, but all three contain stachydrine and leonurine. The EMA considers four species therapeutically equivalent for traditional use purposes. [26],[27]
| Species | Common Name | Primary Use | Key Distinction | Uterotonic Potency |
|---|---|---|---|---|
| L. cardiaca | Motherwort (European) | Cardiac, anxiolytic, antihypertensive | Principal European pharmacopoeial species. French Ph. List A. | Moderate |
| L. japonicus | Chinese motherwort | Obstetric, gynaecological, cardiac (TCM) | Primary TCM species. Strongest uterotonic effect. Injection form used clinically for PPH. [17] | Strong |
| L. sibiricus | Siberian motherwort | Metabolic, cardiovascular | Improves insulin secretion and prevents cardiovascular disorders in L. sibiricus extracts. [24] | Lower |
| L. heterophyllus | Variable-leaf motherwort | Neurological, stroke prevention | Alkaloid extract neuroprotective against cerebral ischaemia-reperfusion injury. Potential in ischaemic stroke prevention. [25] | Not documented |
Quality Marker Note
All three major species contain stachydrine [28] and leonurine [29], but their quantitative ratios differ significantly. Buyers should request HPLC certificates of analysis specifying stachydrine and leonurine content rather than relying on species name alone. European products using L. cardiaca comply with the French Pharmacopoeia minimum of 0.2% hyperoside.
One of the most searched clinical questions in cardiovascular phytomedicine: can motherwort replace beta-blockers for heart rate and blood pressure control? The evidence demands nuance — and honesty.
⚠ Critical Safety Statement
Motherwort is not a pharmacological substitute for beta-blockers. Never discontinue a prescribed beta-blocker without medical supervision. Abrupt beta-blocker withdrawal can trigger rebound tachycardia, angina, and in some cases myocardial infarction. This comparison is provided for patient education only.
| Parameter | Motherwort (L. cardiaca) | Beta-Blockers (e.g. Metoprolol, Atenolol) |
|---|---|---|
| Heart rate reduction | Negative chronotropic via lavandulifolioside; prolongs P-Q interval. [7] | Competitive β1/β2 receptor antagonism — dose-dependent, predictable, quantified. |
| Blood pressure reduction | Documented in clinical trial (Shikov 2011): significant BP reduction in hypertension with anxiety. [12] | First-line antihypertensive with large RCT evidence base; predictable dose-response. |
| Anti-arrhythmic activity | Stachydrine and triterpenic acids reduce arrhythmia in electrophysiology studies. [8] | Class II antiarrhythmic by Vaughan Williams classification. Proven in atrial fibrillation, SVT, post-MI. |
| Anxiolytic effect | Multi-compound GABA-A modulation — clinically meaningful in anxiety-driven cardiac symptoms. [14] | No intrinsic anxiolytic mechanism. Sometimes used off-label for performance anxiety (propranolol). |
| Sleep quality | Clinically improved in Shikov 2011 trial — addresses a real unmet need. [12] | Can impair sleep (vivid dreams, insomnia) — particularly lipophilic agents like metoprolol. |
| Evidence level | 1 clinical trial (Shikov 2011), multiple in vitro / in vivo studies. | Thousands of RCTs, meta-analyses, guideline-recommended for multiple indications. |
| Side effects | Generally well tolerated. [30] No established drug interaction data at clinical scale. | Bradycardia, fatigue, cold extremities, bronchoconstriction (β2), sexual dysfunction, rebound on withdrawal. |
| Contraindications | Pregnancy (absolute). Caution with antihypertensives, anticoagulants. | Severe bradycardia, heart block, decompensated heart failure, asthma (non-selective), COPD. |
| Best-fit patient profile | Mild hypertension + anxiety + insomnia as a multi-symptom cluster. Complementary use under physician oversight. | Moderate-severe hypertension, post-MI, heart failure, arrhythmia, angina — guideline-indicated. |
Clinical Bottom Line
Motherwort occupies a distinct niche: the patient with mild hypertension driven by anxiety and autonomic dysregulation, where the conventional beta-blocker profile (no anxiolytic effect, potential sleep disruption) may not be ideal. Its multi-compound GABA-A modulation addresses the neurological root of the cardiac symptom cluster in a way that beta-blockers simply cannot. However, this advantage applies only in mild, uncomplicated cases. For established cardiovascular disease, post-MI, or arrhythmia requiring rate control, beta-blockers are irreplaceable and motherwort should only be considered as an adjunctive option with medical supervision.
Review of documented adverse effects, contraindications, and patient-specific precautions. Tolerability is generally good in the primary literature. [30]
Han et al. (2013) assessed toxicity of aqueous Leonuri herba extract administered to rats over 13 consecutive weeks and reported no significant toxicity findings, supporting a good safety profile at conventional doses. [30]
The primary review literature (Wojtyniak et al., 2013) confirms generally good tolerability. As with all GABA-A–modulating agents, caution regarding sedation is warranted in patients who drive or operate machinery. [2]
Motherwort (Leonurus cardiaca) is used primarily for cardiovascular conditions — hypertension, cardiac arrhythmia, tachycardia, and nervous heart disorders — as well as for anxiety, insomnia, menstrual disorders accompanying amenorrhoea, and menopausal neurovegetative symptoms. Clinical evidence supports its use in hypertension accompanied by anxiety and sleep disturbance, documented in the Shikov et al. (2011) trial.
Leonurine is a guanidine alkaloid unique to the Leonurus genus. It exerts cardioprotective effects by reducing acute myocardial ischaemia, inhibits platelet aggregation, acts as a vasodilator, prevents myocardial apoptosis induced by hypoxia, improves cognitive dysfunction by modulating glutamate excitotoxicity and inhibiting autophagy, and protects the kidneys against LPS-induced injury and fibrosis by suppressing TGF-β and NF-κB signalling pathways.
No — motherwort is not a pharmacological equivalent of beta-blockers and should never be substituted without medical supervision. However, it does exert negative chronotropic effects (slows heart rate), prolongs the P-Q and Q-T intervals, and has demonstrated antihypertensive activity in a clinical study. It may be considered as a complementary option in mild hypertension with anxiety, under physician guidance, rather than a direct replacement for established cardiovascular medications.
No — absolutely not. Motherwort is contraindicated in pregnancy. The plant exerts uterotonic and oxytocic effects, stimulating uterine contractions and potentially inducing miscarriage or premature labour. This contraindication is absolute, well established in the primary literature, and applies at any dose.
Leonurus japonicus (Chinese motherwort, Yi Mu Cao) is the primary species used in Traditional Chinese Medicine for obstetric and gynaecological conditions, including postpartum haemorrhage prevention and menstrual irregularities. Leonurus cardiaca is the European species more commonly used for cardiovascular and anxiolytic indications. Both contain stachydrine and leonurine, but structural and phytochemical differences exist. The EMA considers L. japonicus, L. artemisia, L. heterophyllus and L. sibiricus therapeutically equivalent to L. cardiaca for traditional use.
The French Pharmacopoeia requires a minimum of 0.2% flavonoids (expressed as hyperoside) in the aerial parts. Available forms include mother tincture and alcoholic tinctures. In the clinical study by Shikov et al. (2011), a motherwort oil extract was administered to hypertensive patients with documented improvements in blood pressure, anxiety, and sleep quality. Specific clinical dosage ranges should always be determined under the guidance of a qualified healthcare practitioner.
Caution is warranted when combining motherwort with antihypertensive drugs (additive hypotensive effect), anticoagulants or antiplatelet agents (leonurine and stachydrine inhibit platelet aggregation), sedatives or anxiolytics (GABA-A receptor interaction may potentiate CNS depression), and potentially cardiac glycosides (mild cardiotonic activity via bufanolide glucosides). Always inform your prescribing physician if you are using motherwort alongside any cardiovascular or neurological medications.
Motherwort's sedative and anxiolytic effects are mediated by multiple compounds that bind to GABA-A receptors. These include isoleosibirine (a labdane-type diterpene), 7R-chloro-6-deoxy-harpagide (an iridoid), lavandulifolioside (a phenylethanoide), stachydrine, and leonurine. This multi-compound GABA-A modulation produces anxiolytic and tranquillising effects without the single-molecule mechanism of conventional benzodiazepines, as confirmed by standardised receptor binding assays in Rauwald et al. (2015).
30 peer-reviewed references. All PubMed links verified at time of publication.